RF – Bicalutamide: An Emergent Treatment Option in Trichology

array:24 ["pii" => "S0001731023006233" "issn" => "00017310" "doi" => "10.1016/j.ad.2022.08.036" "estado" => "S300" "fechaPublicacion" => "2023-10-01" "aid" => "3614" "copyright" => "AEDV" "copyrightAnyo" => "2023" "documento" => "article" "crossmark" => 1 "subdocumento" => "sco" "cita" => "Actas Dermosifiliogr. 2023;114:T812-T815" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "itemSiguiente" => array:18 [ "pii" => "S0001731023001692" "issn" => "00017310" "doi" => "10.1016/j.ad.2022.10.046" "estado" => "S300" "fechaPublicacion" => "2023-10-01" "aid" => "3415" "copyright" => "AEDV" "documento" => "article" "crossmark" => 1 "subdocumento" => "sco" "cita" => "Actas Dermosifiliogr. 2023;114:816-7" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "es" => array:10 [ "idiomaDefecto" => true "cabecera" => "FORO DE RESIDENTES" "titulo" => "FR - Microscopia confocal de reflectancia en el diagnóstico de lesiones pigmentadas equívocas" "tienePdf" => "es" "tieneTextoCompleto" => "es" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "816" "paginaFinal" => "817" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "RF - Reflectance Confocal Microscopy for the Diagnosis of Equivocal Pigmented Lesions" ] ] "contieneTextoCompleto" => array:1 [ "es" => true ] "contienePdf" => array:1 [ "es" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "L. Corbella-Bagot, M. Luque-Luna, D. Morgado-Carrasco" "autores" => array:3 [ 0 => array:2 [ "nombre" => "L." "apellidos" => "Corbella-Bagot" ] 1 => array:2 [ "nombre" => "M." "apellidos" => "Luque-Luna" ] 2 => array:2 [ "nombre" => "D." "apellidos" => "Morgado-Carrasco" ] ] ] ] ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731023001692?idApp=UINPBA000044" "url" => "/00017310/0000011400000009/v1_202310020456/S0001731023001692/v1_202310020456/es/main.assets" ] "itemAnterior" => array:18 [ "pii" => "S0001731023005057" "issn" => "00017310" "doi" => "10.1016/j.ad.2022.08.034" "estado" => "S300" "fechaPublicacion" => "2023-10-01" "aid" => "3562" "copyright" => "AEDV" "documento" => "article" "crossmark" => 1 "subdocumento" => "sco" "cita" => "Actas Dermosifiliogr. 2023;114:812-5" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "es" => array:10 [ "idiomaDefecto" => true "cabecera" => "Foro de Residentes" "titulo" => "FR - Bicalutamida, una realidad emergente en tricología" "tienePdf" => "es" "tieneTextoCompleto" => "es" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "812" "paginaFinal" => "815" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "RF - Bicalutamide: An Emergent Treatment Option in Trichology" ] ] "contieneTextoCompleto" => array:1 [ "es" => true ] "contienePdf" => array:1 [ "es" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "M.D. Pegalajar- García, A. Gil-Villalba, F.J. de la Torre-Gomar" "autores" => array:3 [ 0 => array:2 [ "nombre" => "M.D." "apellidos" => "Pegalajar- García" ] 1 => array:2 [ "nombre" => "A." "apellidos" => "Gil-Villalba" ] 2 => array:2 [ "nombre" => "F.J." "apellidos" => "de la Torre-Gomar" ] ] ] ] ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731023005057?idApp=UINPBA000044" "url" => "/00017310/0000011400000009/v1_202310020456/S0001731023005057/v1_202310020456/es/main.assets" ] "asociados" => array:1 [ 0 => array:18 [ "pii" => "S0001731023005057" "issn" => "00017310" "doi" => "10.1016/j.ad.2022.08.034" "estado" => "S300" "fechaPublicacion" => "2023-10-01" "aid" => "3562" "copyright" => "AEDV" "documento" => "article" "crossmark" => 1 "subdocumento" => "sco" "cita" => "Actas Dermosifiliogr. 2023;114:812-5" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "es" => array:10 [ "idiomaDefecto" => true "cabecera" => "Foro de Residentes" "titulo" => "FR - Bicalutamida, una realidad emergente en tricología" "tienePdf" => "es" "tieneTextoCompleto" => "es" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "812" "paginaFinal" => "815" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "RF - Bicalutamide: An Emergent Treatment Option in Trichology" ] ] "contieneTextoCompleto" => array:1 [ "es" => true ] "contienePdf" => array:1 [ "es" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "M.D. Pegalajar- García, A. Gil-Villalba, F.J. de la Torre-Gomar" "autores" => array:3 [ 0 => array:2 [ "nombre" => "M.D." "apellidos" => "Pegalajar- García" ] 1 => array:2 [ "nombre" => "A." "apellidos" => "Gil-Villalba" ] 2 => array:2 [ "nombre" => "F.J." "apellidos" => "de la Torre-Gomar" ] ] ] ] ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731023005057?idApp=UINPBA000044" "url" => "/00017310/0000011400000009/v1_202310020456/S0001731023005057/v1_202310020456/es/main.assets" ] ] "en" => array:13 [ "idiomaDefecto" => true "cabecera" => "Resident's Forum" "titulo" => " RF – Bicalutamide: An Emergent Treatment Option in Trichology" "tieneTextoCompleto" => true "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "T812" "paginaFinal" => "T815" ] ] "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "M.D. Pegalajar-García, A. Gil-Villalba, F.J. de la Torre-Gomar" "autores" => array:3 [ 0 => array:2 [ "nombre" => "M.D." "apellidos" => "Pegalajar-García" ] 1 => array:2 [ "nombre" => "A." "apellidos" => "Gil-Villalba" ] 2 => array:4 [ "nombre" => "F.J." "apellidos" => "de la Torre-Gomar" "email" => array:1 [ 0 => "fjtogo@gmail.com" ] "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "*" "identificador" => "cor0005" ] ] ] ] "afiliaciones" => array:1 [ 0 => array:2 [ "entidad" => "Servicio de Dermatología, Hospital Clínico Universitario San Cecilio, Granada, Spain" "identificador" => "aff0005" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor0005" "etiqueta" => "⁎" "correspondencia" => "Corresponding author." ] ] ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "FR – Bicalutamida, una realidad emergente en tricología" ] ] "textoCompleto" => "Bicalutamide is a nonsteroidal androgen receptor antagonist approved for treatment of prostate cancer. It is now considered an alternative option in trichology and is used off-label in patients with female pattern hair loss.<a class="elsevierStyleCrossRef" href="#bib0030">1</a>Bicalutamide exerts selective peripheral action in hair follicle dermal papilla cells. At the doses used in trichology, the drug has no mineralocorticoid or glucocorticoid activity, nor does it exert effects on testosterone, estrogen, or progestogen levels.<a class="elsevierStyleCrossRef" href="#bib0035">2</a>There is no agreement on the appropriate dose of bicalutamide for female pattern hair loss, although it is always lower than that administered in prostate cancer. In the largest series to date, Ismail et al.<a class="elsevierStyleCrossRef" href="#bib0035">2</a> found that 10mg/d was the most commonly used dose, whereas Fernandez-Nieto et al.<a class="elsevierStyleCrossRef" href="#bib0030">1</a> found it to be between 25 and 50mg/d. In both studies, bicalutamide was generally administered in combination with other drugs, mainly oral minoxidil at 0.5–1mg/d and, albeit to a lesser extent, with spironolactone.<a class="elsevierStyleCrossRefs" href="#bib0030">1,2</a> The time to improvement varied between 6 months and 2 years, with an improvement of 20.2–27.5% on the Sinclair scale at 6 months<a class="elsevierStyleCrossRefs" href="#bib0030">1,2</a> (<a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a>).<elsevierMultimedia ident="tbl0005"></elsevierMultimedia>Given the antiandrogenic activity of bicalutamide, some studies suggest that treatment at a mean dose of 14.4mg/d combined with oral minoxidil at a mean dose of 1.5mg/d for more than 3 months could reduce minoxidil-induced hypertrichosis, thus enabling better tolerance to higher doses of the drug and optimizing treatment of female pattern hair loss.<a class="elsevierStyleCrossRef" href="#bib0040">3</a>Given its role in miniaturization of the follicle and the above-mentioned effect, the drug was used successfully in a patient with central centrifugal alopecia at 10mg/d in combination with 0.45mg/d of oral minoxidil and a topical corticosteroid.<a class="elsevierStyleCrossRef" href="#bib0045">4</a>Published studies have shown bicalutamide to have a good safety and tolerability profile.<a class="elsevierStyleCrossRefs" href="#bib0030">1–3</a> The most common adverse effect was hepatotoxicity, with elevated transaminases in 2.9–12.5% of cases and values lower than three times the upper limit of normal in all cases.<a class="elsevierStyleCrossRef" href="#bib0050">5</a> This effect is dose-dependent, with most cases improving spontaneously or after reducing the dose of bicalutamide, without the need for discontinuation. Other less common undesirable effects included gastrointestinal disorders, swollen limbs, breast pain, and migraine (<a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a>).<a class="elsevierStyleCrossRefs" href="#bib0030">1–3</a>Bicalutamide is contraindicated in pregnant women and should be administered with caution in women with a personal or family history of hormone-dependent tumors.<a class="elsevierStyleCrossRef" href="#bib0050">5</a>Current evidence points to the need for a blood analysis before initiating therapy with bicalutamide (complete blood count, creatinine, liver enzymes, lipid profile, and prothrombin time). The analysis should be repeated every 3–6 months.<a class="elsevierStyleCrossRefs" href="#bib0035">2,5</a>Advances in our knowledge of bicalutamide in recent years have enabled us to evaluate it as an important alternative in the treatment of female pattern hair loss, especially in premenopausal patients with other features of hyperandrogenism such as acne, hirsutism, and seborrhea.<a class="elsevierStyleCrossRef" href="#bib0030">1</a> More evidence is necessary to confirm the safety and efficacy profile of bicalutamide and to standardize dosing. However, a dose of 10–50mg/d seems to be both safe and effective in monotherapy or in combination with other drugs." "pdfFichero" => "main.pdf" "tienePdf" => true "PalabrasClave" => array:1 [ "en" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Keywords" "identificador" => "xpalclavsec1702495" "palabras" => array:4 [ 0 => "Androgenetic alopecia" 1 => "Bicalutamide" 2 => "Minoxidil" 3 => "Hypertrichosis" ] ] ] ] "multimedia" => array:1 [ 0 => array:8 [ "identificador" => "tbl0005" "etiqueta" => "Table 1" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at1" "detalle" => "Table " "rol" => "short" ] ] "tabla" => array:3 [ "leyenda" => "Abbreviation: FPHL, female pattern hair loss." "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Authors \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Study type \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Disease treated \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">No. of patients treated \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Dose, mg/d (% of patients treated) \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Concomitant drugs (% of patients treated) \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Duration of treatment, mo \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Initial time of improvement measured, mo \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Results at 6 mo, % reduction in Sinclair score \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Adverse effects(% patients affected) \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">No. (%) of patients discontinuing treatment owing to adverse effects \t\t\t\t\t\t\n \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Ismail et al.<a class="elsevierStyleCrossRef" href="#bib0035">2</a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Case series \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">FPHL \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">316 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">-10 (69.6%)-12.5 (2.5%)-20 (25%)-25 (1%)-30 (1.6%)-50 (0.3%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">-Oral minoxidil<a class="elsevierStyleCrossRef" href="#tblfn0005">a</a> (97.4%)-Spironolactone<a class="elsevierStyleCrossRef" href="#tblfn0010">b</a>(54.4%)-Monotherapy (1.8%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">2–69(mean, 6.21) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">3 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">20.2 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">-Elevated transaminases (2.9%)-Swollen limbs (2.5%)-Gastrointestinal disorders (1.9%)-In <1% of cases, respectively, breast pain, acneiform eruption, asthenia, myalgia, decreased libido, menstrual disorders, mood changes, palpitations, dyspnea, photosensitivity \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">13(4.1%) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Fernandez-Nieto et al.<a class="elsevierStyleCrossRef" href="#bib0030">1</a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Case series \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">FPHL \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">44 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">-25 (34.1%)-50 (65.9%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">-Oral minoxidil 0.5–1mg/d (75.0%)-Oral dutasteride 0.5mg/d (15.9%)-Mesotherapy with dutasteride (13.6%)-Topical minoxidil 5% (11.4%)-Monotherapy (6.8%)-Oral finasteride 2.5mg/d (2.3%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">2–24(mean, 10.5) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">6 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">27.5 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">-Elevated transaminases (11.4%)-Effluvium (6.8%)-Menstrual disorders (4.5%)-Migraine (2.2%)-Endometrial hyperplasia (2.2%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Moussa et al.<a class="elsevierStyleCrossRef" href="#bib0040">3</a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Case series \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Minoxidil-induced hypertrichosis in FPHL \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">35 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">-10 (57%)-20 (40%)-25 (3%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">-Oral minoxidil 0.25–10mg/d [mean dose 1.5mg/d](100%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">28.9(mean, 25.92) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">3.4 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">19.1 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">-Elevated transaminases (6%)-Scalp dysesthesia (3%)-Migraine (3%)-Periorbital edema (3%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">2(5.7%) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Lobon et al.<a class="elsevierStyleCrossRef" href="#bib0045">4</a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Case study \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Centrifugal central alopecia \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">1 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">10, with increase to 20 (100%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">-Oral minoxidil 0.45mg/d and topical clobetasol dipropionate 0.05%(100%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">– \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">4 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">– \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">– \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0 \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab3295039.png" ] ] ] "notaPie" => array:2 [ 0 => array:3 [ "identificador" => "tblfn0005" "etiqueta" => "a" "nota" => "Dose of oral minoxidil not specified." ] 1 => array:3 [ "identificador" => "tblfn0010" "etiqueta" => "b" "nota" => "Dose of spironolactone not specified." ] ] ] "descripcion" => array:1 [ "en" => "Summary of the current literature on the use of bicalutamide in trichology." ] ] ] "bibliografia" => array:2 [ "titulo" => "References" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bibs0015" "bibliografiaReferencia" => array:5 [ 0 => array:3 [ "identificador" => "bib0030" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Bicalutamide: a potential new oral antiandrogenic drug for female pattern hair loss" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "D. Fernandez-Nieto" 1 => "D. Saceda-Corralo" 2 => "J. Jimenez-Cauhe" 3 => "O.M. Moreno-Arrones" 4 => "R. Rodrigues-Barata" 5 => "A. Hermosa-Gelbard" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.jaad.2020.04.0544" "Revista" => array:6 [ "tituloSerie" => "J Am Acad Dermatol [Internet]" "fecha" => "2020" "volumen" => "83" "paginaInicial" => "e355" "paginaFinal" => "e356" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/32320770" "web" => "Medline" ] ] ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib0035" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Safety of oral bicalutamide in female pattern hair loss: a retrospective review of 316 patients" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "F.F. Ismail" 1 => "N. Meah" 2 => "L. Trindade de Carvalho" 3 => "B. Bhoyrul" 4 => "D. Wall" 5 => "R. Sinclair" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.jaad.2020.03.034" "Revista" => array:6 [ "tituloSerie" => "J Am Acad Dermatol [Internet]" "fecha" => "2020" "volumen" => "83" "paginaInicial" => "1478" "paginaFinal" => "1479" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/32213304" "web" => "Medline" ] ] ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib0040" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Bicalutamide improves minoxidil-induced hypertrichosis in female pattern hair loss: a retrospective review of 35 patients" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "A. Moussa" 1 => "A. Kazmi" 2 => "L. Bokhari" 3 => "R.D. Sinclair" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.jaad.2021.10.048" "Revista" => array:6 [ "tituloSerie" => "J Am Acad Dermatol" "fecha" => "2022" "volumen" => "87" "paginaInicial" => "488" "paginaFinal" => "490" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/34740752" "web" => "Medline" ] ] ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bib0045" "etiqueta" => "4" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Significant hair regrowth in a Middle Eastern woman with central centrifugal cicatricial alopecia" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "K. Lobon" 1 => "J. Pinczewski" 2 => "B. Bhoyrul" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/ced.14822" "Revista" => array:6 [ "tituloSerie" => "Clin Exp Dermatol [Internet]" "fecha" => "2022" "volumen" => "47" "paginaInicial" => "136" "paginaFinal" => "138" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/34192377" "web" => "Medline" ] ] ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bib0050" "etiqueta" => "5" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Bicalutamide and the new perspectives for female pattern hair loss treatment: what dermatologists should know" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "R.M. Carvalho" 1 => "L.D.N. Santos" 2 => "P.M. Ramos" 3 => "C.J. Machado" 4 => "P. Acioly" 5 => "S.C. Frattini" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/jocd.14773" "Revista" => array:7 [ "tituloSerie" => "J Cosmet Dermatol" "fecha" => "2022" "volumen" => "21" "paginaInicial" => "4171" "paginaFinal" => "4175" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/35032336" "web" => "Medline" ] ] "itemHostRev" => array:3 [ "pii" => "S147444221730371X" "estado" => "S300" "issn" => "14744422" ] ] ] ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "en" "url" => "/00017310/0000011400000009/v1_202310020456/S0001731023006233/v1_202310020456/en/main.assets" "Apartado" => array:4 [ "identificador" => "34907" "tipo" => "SECCION" "es" => array:2 [ "titulo" => "Foro de Residentes" "idiomaDefecto" => true ] "idiomaDefecto" => "es" ] "PDF" => "https://static.elsevier.es/multimedia/00017310/0000011400000009/v1_202310020456/S0001731023006233/v1_202310020456/en/main.pdf?idApp=UINPBA000044&text.app=https://actasdermo.org/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731023006233?idApp=UINPBA000044"]

Estadísticas

Resident's Forum

RF – Bicalutamide: An Emergent Treatment Option in Trichology

FR – Bicalutamida, una realidad emergente en tricología

M.D. Pegalajar-García, A. Gil-Villalba, F.J. de la Torre-Gomar

Autor para correspondencia

fjtogo@gmail.com

Corresponding author.

Servicio de Dermatología, Hospital Clínico Universitario San Cecilio, Granada, Spain

Leído

4981

Veces
se ha leído el artículo

1228

Total PDF

3753

Total HTML

Compartir estadísticas

 array:24 [
  "pii" => "S0001731023006233"
  "issn" => "00017310"
  "doi" => "10.1016/j.ad.2022.08.036"
  "estado" => "S300"
  "fechaPublicacion" => "2023-10-01"
  "aid" => "3614"
  "copyright" => "AEDV"
  "copyrightAnyo" => "2023"
  "documento" => "article"
  "crossmark" => 1
  "subdocumento" => "sco"
  "cita" => "Actas Dermosifiliogr. 2023;114:T812-T815"
  "abierto" => array:3 [
    "ES" => true
    "ES2" => true
    "LATM" => true
  ]
  "gratuito" => true
  "lecturas" => array:1 [
    "total" => 0
  ]
  "itemSiguiente" => array:18 [
    "pii" => "S0001731023001692"
    "issn" => "00017310"
    "doi" => "10.1016/j.ad.2022.10.046"
    "estado" => "S300"
    "fechaPublicacion" => "2023-10-01"
    "aid" => "3415"
    "copyright" => "AEDV"
    "documento" => "article"
    "crossmark" => 1
    "subdocumento" => "sco"
    "cita" => "Actas Dermosifiliogr. 2023;114:816-7"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:1 [
      "total" => 0
    ]
    "es" => array:10 [
      "idiomaDefecto" => true
      "cabecera" => "<span class="elsevierStyleTextfn">FORO DE RESIDENTES</span>"
      "titulo" => "FR - Microscopia confocal de reflectancia en el diagn&#243;stico de lesiones pigmentadas equ&#237;vocas"
      "tienePdf" => "es"
      "tieneTextoCompleto" => "es"
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "816"
          "paginaFinal" => "817"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "en" => array:1 [
          "titulo" => "RF - Reflectance Confocal Microscopy for the Diagnosis of Equivocal Pigmented Lesions"
        ]
      ]
      "contieneTextoCompleto" => array:1 [
        "es" => true
      ]
      "contienePdf" => array:1 [
        "es" => true
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "L&#46; Corbella-Bagot, M&#46; Luque-Luna, D&#46; Morgado-Carrasco"
          "autores" => array:3 [
            0 => array:2 [
              "nombre" => "L&#46;"
              "apellidos" => "Corbella-Bagot"
            ]
            1 => array:2 [
              "nombre" => "M&#46;"
              "apellidos" => "Luque-Luna"
            ]
            2 => array:2 [
              "nombre" => "D&#46;"
              "apellidos" => "Morgado-Carrasco"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "es"
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731023001692?idApp=UINPBA000044"
    "url" => "/00017310/0000011400000009/v1_202310020456/S0001731023001692/v1_202310020456/es/main.assets"
  ]
  "itemAnterior" => array:18 [
    "pii" => "S0001731023005057"
    "issn" => "00017310"
    "doi" => "10.1016/j.ad.2022.08.034"
    "estado" => "S300"
    "fechaPublicacion" => "2023-10-01"
    "aid" => "3562"
    "copyright" => "AEDV"
    "documento" => "article"
    "crossmark" => 1
    "subdocumento" => "sco"
    "cita" => "Actas Dermosifiliogr. 2023;114:812-5"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:1 [
      "total" => 0
    ]
    "es" => array:10 [
      "idiomaDefecto" => true
      "cabecera" => "<span class="elsevierStyleTextfn">Foro de Residentes</span>"
      "titulo" => "FR - Bicalutamida&#44; una realidad emergente en tricolog&#237;a"
      "tienePdf" => "es"
      "tieneTextoCompleto" => "es"
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "812"
          "paginaFinal" => "815"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "en" => array:1 [
          "titulo" => "RF - Bicalutamide&#58; An Emergent Treatment Option in Trichology"
        ]
      ]
      "contieneTextoCompleto" => array:1 [
        "es" => true
      ]
      "contienePdf" => array:1 [
        "es" => true
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "M&#46;D&#46; Pegalajar- Garc&#237;a, A&#46; Gil-Villalba, F&#46;J&#46; de la Torre-Gomar"
          "autores" => array:3 [
            0 => array:2 [
              "nombre" => "M&#46;D&#46;"
              "apellidos" => "Pegalajar- Garc&#237;a"
            ]
            1 => array:2 [
              "nombre" => "A&#46;"
              "apellidos" => "Gil-Villalba"
            ]
            2 => array:2 [
              "nombre" => "F&#46;J&#46;"
              "apellidos" => "de la Torre-Gomar"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "es"
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731023005057?idApp=UINPBA000044"
    "url" => "/00017310/0000011400000009/v1_202310020456/S0001731023005057/v1_202310020456/es/main.assets"
  ]
  "asociados" => array:1 [
    0 => array:18 [
      "pii" => "S0001731023005057"
      "issn" => "00017310"
      "doi" => "10.1016/j.ad.2022.08.034"
      "estado" => "S300"
      "fechaPublicacion" => "2023-10-01"
      "aid" => "3562"
      "copyright" => "AEDV"
      "documento" => "article"
      "crossmark" => 1
      "subdocumento" => "sco"
      "cita" => "Actas Dermosifiliogr. 2023;114:812-5"
      "abierto" => array:3 [
        "ES" => true
        "ES2" => true
        "LATM" => true
      ]
      "gratuito" => true
      "lecturas" => array:1 [
        "total" => 0
      ]
      "es" => array:10 [
        "idiomaDefecto" => true
        "cabecera" => "<span class="elsevierStyleTextfn">Foro de Residentes</span>"
        "titulo" => "FR - Bicalutamida&#44; una realidad emergente en tricolog&#237;a"
        "tienePdf" => "es"
        "tieneTextoCompleto" => "es"
        "paginas" => array:1 [
          0 => array:2 [
            "paginaInicial" => "812"
            "paginaFinal" => "815"
          ]
        ]
        "titulosAlternativos" => array:1 [
          "en" => array:1 [
            "titulo" => "RF - Bicalutamide&#58; An Emergent Treatment Option in Trichology"
          ]
        ]
        "contieneTextoCompleto" => array:1 [
          "es" => true
        ]
        "contienePdf" => array:1 [
          "es" => true
        ]
        "autores" => array:1 [
          0 => array:2 [
            "autoresLista" => "M&#46;D&#46; Pegalajar- Garc&#237;a, A&#46; Gil-Villalba, F&#46;J&#46; de la Torre-Gomar"
            "autores" => array:3 [
              0 => array:2 [
                "nombre" => "M&#46;D&#46;"
                "apellidos" => "Pegalajar- Garc&#237;a"
              ]
              1 => array:2 [
                "nombre" => "A&#46;"
                "apellidos" => "Gil-Villalba"
              ]
              2 => array:2 [
                "nombre" => "F&#46;J&#46;"
                "apellidos" => "de la Torre-Gomar"
              ]
            ]
          ]
        ]
      ]
      "idiomaDefecto" => "es"
      "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731023005057?idApp=UINPBA000044"
      "url" => "/00017310/0000011400000009/v1_202310020456/S0001731023005057/v1_202310020456/es/main.assets"
    ]
  ]
  "en" => array:13 [
    "idiomaDefecto" => true
    "cabecera" => "<span class="elsevierStyleTextfn">Resident&#39;s Forum</span>"
    "titulo" => " RF &#8211; Bicalutamide&#58; An Emergent Treatment Option in Trichology"
    "tieneTextoCompleto" => true
    "paginas" => array:1 [
      0 => array:2 [
        "paginaInicial" => "T812"
        "paginaFinal" => "T815"
      ]
    ]
    "autores" => array:1 [
      0 => array:4 [
        "autoresLista" => "M&#46;D&#46; Pegalajar-Garc&#237;a, A&#46; Gil-Villalba, F&#46;J&#46; de la Torre-Gomar"
        "autores" => array:3 [
          0 => array:2 [
            "nombre" => "M&#46;D&#46;"
            "apellidos" => "Pegalajar-Garc&#237;a"
          ]
          1 => array:2 [
            "nombre" => "A&#46;"
            "apellidos" => "Gil-Villalba"
          ]
          2 => array:4 [
            "nombre" => "F&#46;J&#46;"
            "apellidos" => "de la Torre-Gomar"
            "email" => array:1 [
              0 => "fjtogo@gmail.com"
            ]
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">&#42;</span>"
                "identificador" => "cor0005"
              ]
            ]
          ]
        ]
        "afiliaciones" => array:1 [
          0 => array:2 [
            "entidad" => "Servicio de Dermatolog&#237;a&#44; Hospital Cl&#237;nico Universitario San Cecilio&#44; Granada&#44; Spain"
            "identificador" => "aff0005"
          ]
        ]
        "correspondencia" => array:1 [
          0 => array:3 [
            "identificador" => "cor0005"
            "etiqueta" => "&#8270;"
            "correspondencia" => "Corresponding author&#46;"
          ]
        ]
      ]
    ]
    "titulosAlternativos" => array:1 [
      "es" => array:1 [
        "titulo" => "FR &#8211; Bicalutamida&#44; una realidad emergente en tricolog&#237;a"
      ]
    ]
    "textoCompleto" => "<span class="elsevierStyleSections"><p id="par0005" class="elsevierStylePara elsevierViewall">Bicalutamide is a nonsteroidal androgen receptor antagonist approved for treatment of prostate cancer&#46; It is now considered an alternative option in trichology and is used off-label in patients with female pattern hair loss&#46;<a class="elsevierStyleCrossRef" href="#bib0030"><span class="elsevierStyleSup">1</span></a></p><p id="par0010" class="elsevierStylePara elsevierViewall">Bicalutamide exerts selective peripheral action in hair follicle dermal papilla cells&#46; At the doses used in trichology&#44; the drug has no mineralocorticoid or glucocorticoid activity&#44; nor does it exert effects on testosterone&#44; estrogen&#44; or progestogen levels&#46;<a class="elsevierStyleCrossRef" href="#bib0035"><span class="elsevierStyleSup">2</span></a></p><p id="par0015" class="elsevierStylePara elsevierViewall">There is no agreement on the appropriate dose of bicalutamide for female pattern hair loss&#44; although it is always lower than that administered in prostate cancer&#46; In the largest series to date&#44; Ismail et al&#46;<a class="elsevierStyleCrossRef" href="#bib0035"><span class="elsevierStyleSup">2</span></a> found that 10<span class="elsevierStyleHsp" style=""></span>mg&#47;d was the most commonly used dose&#44; whereas Fernandez-Nieto et al&#46;<a class="elsevierStyleCrossRef" href="#bib0030"><span class="elsevierStyleSup">1</span></a> found it to be between 25 and 50<span class="elsevierStyleHsp" style=""></span>mg&#47;d&#46; In both studies&#44; bicalutamide was generally administered in combination with other drugs&#44; mainly oral minoxidil at 0&#46;5&#8211;1<span class="elsevierStyleHsp" style=""></span>mg&#47;d and&#44; albeit to a lesser extent&#44; with spironolactone&#46;<a class="elsevierStyleCrossRefs" href="#bib0030"><span class="elsevierStyleSup">1&#44;2</span></a> The time to improvement varied between 6 months and 2 years&#44; with an improvement of 20&#46;2&#8211;27&#46;5&#37; on the Sinclair scale at 6 months<a class="elsevierStyleCrossRefs" href="#bib0030"><span class="elsevierStyleSup">1&#44;2</span></a> &#40;<a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a>&#41;&#46;</p><elsevierMultimedia ident="tbl0005"></elsevierMultimedia><p id="par0020" class="elsevierStylePara elsevierViewall">Given the antiandrogenic activity of bicalutamide&#44; some studies suggest that treatment at a mean dose of 14&#46;4<span class="elsevierStyleHsp" style=""></span>mg&#47;d combined with oral minoxidil at a mean dose of 1&#46;5<span class="elsevierStyleHsp" style=""></span>mg&#47;d for more than 3 months could reduce minoxidil-induced hypertrichosis&#44; thus enabling better tolerance to higher doses of the drug and optimizing treatment of female pattern hair loss&#46;<a class="elsevierStyleCrossRef" href="#bib0040"><span class="elsevierStyleSup">3</span></a></p><p id="par0025" class="elsevierStylePara elsevierViewall">Given its role in miniaturization of the follicle and the above-mentioned effect&#44; the drug was used successfully in a patient with central centrifugal alopecia at 10<span class="elsevierStyleHsp" style=""></span>mg&#47;d in combination with 0&#46;45<span class="elsevierStyleHsp" style=""></span>mg&#47;d of oral minoxidil and a topical corticosteroid&#46;<a class="elsevierStyleCrossRef" href="#bib0045"><span class="elsevierStyleSup">4</span></a></p><p id="par0030" class="elsevierStylePara elsevierViewall">Published studies have shown bicalutamide to have a good safety and tolerability profile&#46;<a class="elsevierStyleCrossRefs" href="#bib0030"><span class="elsevierStyleSup">1&#8211;3</span></a> The most common adverse effect was hepatotoxicity&#44; with elevated transaminases in 2&#46;9&#8211;12&#46;5&#37; of cases and values lower than three times the upper limit of normal in all cases&#46;<a class="elsevierStyleCrossRef" href="#bib0050"><span class="elsevierStyleSup">5</span></a> This effect is dose-dependent&#44; with most cases improving spontaneously or after reducing the dose of bicalutamide&#44; without the need for discontinuation&#46; Other less common undesirable effects included gastrointestinal disorders&#44; swollen limbs&#44; breast pain&#44; and migraine &#40;<a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a>&#41;&#46;<a class="elsevierStyleCrossRefs" href="#bib0030"><span class="elsevierStyleSup">1&#8211;3</span></a></p><p id="par0035" class="elsevierStylePara elsevierViewall">Bicalutamide is contraindicated in pregnant women and should be administered with caution in women with a personal or family history of hormone-dependent tumors&#46;<a class="elsevierStyleCrossRef" href="#bib0050"><span class="elsevierStyleSup">5</span></a></p><p id="par0040" class="elsevierStylePara elsevierViewall">Current evidence points to the need for a blood analysis before initiating therapy with bicalutamide &#40;complete blood count&#44; creatinine&#44; liver enzymes&#44; lipid profile&#44; and prothrombin time&#41;&#46; The analysis should be repeated every 3&#8211;6 months&#46;<a class="elsevierStyleCrossRefs" href="#bib0035"><span class="elsevierStyleSup">2&#44;5</span></a></p><p id="par0045" class="elsevierStylePara elsevierViewall">Advances in our knowledge of bicalutamide in recent years have enabled us to evaluate it as an important alternative in the treatment of female pattern hair loss&#44; especially in premenopausal patients with other features of hyperandrogenism such as acne&#44; hirsutism&#44; and seborrhea&#46;<a class="elsevierStyleCrossRef" href="#bib0030"><span class="elsevierStyleSup">1</span></a> More evidence is necessary to confirm the safety and efficacy profile of bicalutamide and to standardize dosing&#46; However&#44; a dose of 10&#8211;50<span class="elsevierStyleHsp" style=""></span>mg&#47;d seems to be both safe and effective in monotherapy or in combination with other drugs&#46;</p></span>"
    "pdfFichero" => "main.pdf"
    "tienePdf" => true
    "PalabrasClave" => array:1 [
      "en" => array:1 [
        0 => array:4 [
          "clase" => "keyword"
          "titulo" => "Keywords"
          "identificador" => "xpalclavsec1702495"
          "palabras" => array:4 [
            0 => "Androgenetic alopecia"
            1 => "Bicalutamide"
            2 => "Minoxidil"
            3 => "Hypertrichosis"
          ]
        ]
      ]
    ]
    "multimedia" => array:1 [
      0 => array:8 [
        "identificador" => "tbl0005"
        "etiqueta" => "Table 1"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at1"
            "detalle" => "Table "
            "rol" => "short"
          ]
        ]
        "tabla" => array:3 [
          "leyenda" => "<p id="spar0010" class="elsevierStyleSimplePara elsevierViewall"><span class="elsevierStyleItalic">Abbreviation</span>&#58; FPHL&#44; female pattern hair loss&#46;</p>"
          "tablatextoimagen" => array:1 [
            0 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Authors&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Study type&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Disease treated&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">No&#46; of patients treated&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Dose&#44; mg&#47;d &#40;&#37; of patients treated&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Concomitant drugs &#40;&#37; of patients treated&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Duration of treatment&#44; mo&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Initial time of improvement measured&#44; mo&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Results at 6 mo&#44; &#37; reduction in Sinclair score&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Adverse effects&#40;&#37; patients affected&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">No&#46; &#40;&#37;&#41; of patients discontinuing treatment owing to adverse effects&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Ismail et al&#46;<a class="elsevierStyleCrossRef" href="#bib0035"><span class="elsevierStyleSup">2</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Case series&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">FPHL&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">316&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">-10 &#40;69&#46;6&#37;&#41;-12&#46;5 &#40;2&#46;5&#37;&#41;-20 &#40;25&#37;&#41;-25 &#40;1&#37;&#41;-30 &#40;1&#46;6&#37;&#41;-50 &#40;0&#46;3&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">-Oral minoxidil<a class="elsevierStyleCrossRef" href="#tblfn0005"><span class="elsevierStyleSup">a</span></a> &#40;97&#46;4&#37;&#41;-Spironolactone<a class="elsevierStyleCrossRef" href="#tblfn0010"><span class="elsevierStyleSup">b</span></a>&#40;54&#46;4&#37;&#41;-Monotherapy &#40;1&#46;8&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">2&#8211;69&#40;mean&#44; 6&#46;21&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">3&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">20&#46;2&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">-Elevated transaminases &#40;2&#46;9&#37;&#41;-Swollen limbs &#40;2&#46;5&#37;&#41;-Gastrointestinal disorders &#40;1&#46;9&#37;&#41;-In &#60;1&#37; of cases&#44; respectively&#44; breast pain&#44; acneiform eruption&#44; asthenia&#44; myalgia&#44; decreased libido&#44; menstrual disorders&#44; mood changes&#44; palpitations&#44; dyspnea&#44; photosensitivity&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">13&#40;4&#46;1&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Fernandez-Nieto et al&#46;<a class="elsevierStyleCrossRef" href="#bib0030"><span class="elsevierStyleSup">1</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Case series&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">FPHL&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">44&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">-25 &#40;34&#46;1&#37;&#41;-50 &#40;65&#46;9&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">-Oral minoxidil 0&#46;5&#8211;1<span class="elsevierStyleHsp" style=""></span>mg&#47;d &#40;75&#46;0&#37;&#41;-Oral dutasteride 0&#46;5<span class="elsevierStyleHsp" style=""></span>mg&#47;d &#40;15&#46;9&#37;&#41;-Mesotherapy with dutasteride &#40;13&#46;6&#37;&#41;-Topical minoxidil 5&#37; &#40;11&#46;4&#37;&#41;-Monotherapy &#40;6&#46;8&#37;&#41;-Oral finasteride 2&#46;5<span class="elsevierStyleHsp" style=""></span>mg&#47;d &#40;2&#46;3&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">2&#8211;24&#40;mean&#44; 10&#46;5&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">6&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">27&#46;5&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">-Elevated transaminases &#40;11&#46;4&#37;&#41;-Effluvium &#40;6&#46;8&#37;&#41;-Menstrual disorders &#40;4&#46;5&#37;&#41;-Migraine &#40;2&#46;2&#37;&#41;-Endometrial hyperplasia &#40;2&#46;2&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">0&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Moussa et al&#46;<a class="elsevierStyleCrossRef" href="#bib0040"><span class="elsevierStyleSup">3</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Case series&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Minoxidil-induced hypertrichosis in FPHL&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">35&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">-10 &#40;57&#37;&#41;-20 &#40;40&#37;&#41;-25 &#40;3&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">-Oral minoxidil 0&#46;25&#8211;10<span class="elsevierStyleHsp" style=""></span>mg&#47;d &#91;mean dose 1&#46;5<span class="elsevierStyleHsp" style=""></span>mg&#47;d&#93;&#40;100&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">28&#46;9&#40;mean&#44; 25&#46;92&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">3&#46;4&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">19&#46;1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">-Elevated transaminases &#40;6&#37;&#41;-Scalp dysesthesia &#40;3&#37;&#41;-Migraine &#40;3&#37;&#41;-Periorbital edema &#40;3&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">2&#40;5&#46;7&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Lobon et al&#46;<a class="elsevierStyleCrossRef" href="#bib0045"><span class="elsevierStyleSup">4</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Case study&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Centrifugal central alopecia&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">10&#44; with increase to 20 &#40;100&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">-Oral minoxidil 0&#46;45<span class="elsevierStyleHsp" style=""></span>mg&#47;d and topical clobetasol dipropionate 0&#46;05&#37;&#40;100&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&#8211;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">4&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&#8211;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&#8211;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">0&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab3295039.png"
              ]
            ]
          ]
          "notaPie" => array:2 [
            0 => array:3 [
              "identificador" => "tblfn0005"
              "etiqueta" => "a"
              "nota" => "<p class="elsevierStyleNotepara" id="npar0005">Dose of oral minoxidil not specified&#46;</p>"
            ]
            1 => array:3 [
              "identificador" => "tblfn0010"
              "etiqueta" => "b"
              "nota" => "<p class="elsevierStyleNotepara" id="npar0010">Dose of spironolactone not specified&#46;</p>"
            ]
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Summary of the current literature on the use of bicalutamide in trichology&#46;</p>"
        ]
      ]
    ]
    "bibliografia" => array:2 [
      "titulo" => "References"
      "seccion" => array:1 [
        0 => array:2 [
          "identificador" => "bibs0015"
          "bibliografiaReferencia" => array:5 [
            0 => array:3 [
              "identificador" => "bib0030"
              "etiqueta" => "1"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Bicalutamide&#58; a potential new oral antiandrogenic drug for female pattern hair loss"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "D&#46; Fernandez-Nieto"
                            1 => "D&#46; Saceda-Corralo"
                            2 => "J&#46; Jimenez-Cauhe"
                            3 => "O&#46;M&#46; Moreno-Arrones"
                            4 => "R&#46; Rodrigues-Barata"
                            5 => "A&#46; Hermosa-Gelbard"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.jaad.2020.04.0544"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Am Acad Dermatol &#91;Internet&#93;"
                        "fecha" => "2020"
                        "volumen" => "83"
                        "paginaInicial" => "e355"
                        "paginaFinal" => "e356"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/32320770"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            1 => array:3 [
              "identificador" => "bib0035"
              "etiqueta" => "2"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Safety of oral bicalutamide in female pattern hair loss&#58; a retrospective review of 316 patients"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:6 [
                            0 => "F&#46;F&#46; Ismail"
                            1 => "N&#46; Meah"
                            2 => "L&#46; Trindade de Carvalho"
                            3 => "B&#46; Bhoyrul"
                            4 => "D&#46; Wall"
                            5 => "R&#46; Sinclair"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.jaad.2020.03.034"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Am Acad Dermatol &#91;Internet&#93;"
                        "fecha" => "2020"
                        "volumen" => "83"
                        "paginaInicial" => "1478"
                        "paginaFinal" => "1479"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/32213304"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            2 => array:3 [
              "identificador" => "bib0040"
              "etiqueta" => "3"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Bicalutamide improves minoxidil-induced hypertrichosis in female pattern hair loss&#58; a retrospective review of 35 patients"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:4 [
                            0 => "A&#46; Moussa"
                            1 => "A&#46; Kazmi"
                            2 => "L&#46; Bokhari"
                            3 => "R&#46;D&#46; Sinclair"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.jaad.2021.10.048"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Am Acad Dermatol"
                        "fecha" => "2022"
                        "volumen" => "87"
                        "paginaInicial" => "488"
                        "paginaFinal" => "490"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/34740752"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            3 => array:3 [
              "identificador" => "bib0045"
              "etiqueta" => "4"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Significant hair regrowth in a Middle Eastern woman with central centrifugal cicatricial alopecia"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:3 [
                            0 => "K&#46; Lobon"
                            1 => "J&#46; Pinczewski"
                            2 => "B&#46; Bhoyrul"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/ced.14822"
                      "Revista" => array:6 [
                        "tituloSerie" => "Clin Exp Dermatol &#91;Internet&#93;"
                        "fecha" => "2022"
                        "volumen" => "47"
                        "paginaInicial" => "136"
                        "paginaFinal" => "138"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/34192377"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            4 => array:3 [
              "identificador" => "bib0050"
              "etiqueta" => "5"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Bicalutamide and the new perspectives for female pattern hair loss treatment&#58; what dermatologists should know"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "R&#46;M&#46; Carvalho"
                            1 => "L&#46;D&#46;N&#46; Santos"
                            2 => "P&#46;M&#46; Ramos"
                            3 => "C&#46;J&#46; Machado"
                            4 => "P&#46; Acioly"
                            5 => "S&#46;C&#46; Frattini"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/jocd.14773"
                      "Revista" => array:7 [
                        "tituloSerie" => "J Cosmet Dermatol"
                        "fecha" => "2022"
                        "volumen" => "21"
                        "paginaInicial" => "4171"
                        "paginaFinal" => "4175"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/35032336"
                            "web" => "Medline"
                          ]
                        ]
                        "itemHostRev" => array:3 [
                          "pii" => "S147444221730371X"
                          "estado" => "S300"
                          "issn" => "14744422"
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
          ]
        ]
      ]
    ]
  ]
  "idiomaDefecto" => "en"
  "url" => "/00017310/0000011400000009/v1_202310020456/S0001731023006233/v1_202310020456/en/main.assets"
  "Apartado" => array:4 [
    "identificador" => "34907"
    "tipo" => "SECCION"
    "es" => array:2 [
      "titulo" => "Foro de Residentes"
      "idiomaDefecto" => true
    ]
    "idiomaDefecto" => "es"
  ]
  "PDF" => "https://static.elsevier.es/multimedia/00017310/0000011400000009/v1_202310020456/S0001731023006233/v1_202310020456/en/main.pdf?idApp=UINPBA000044&text.app=https://actasdermo.org/"
  "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731023006233?idApp=UINPBA000044"
]

Información del artículo

ISSN: 00017310
Idioma original: Inglés

DOI:10.1016/j.ad.2022.08.036

Datos actualizados diariamente

año/Mes	Html	Pdf	Total

2024 Noviembre	44	16	60
2024 Octubre	280	87	367
2024 Septiembre	330	72	402
2024 Agosto	408	99	507
2024 Julio	406	74	480
2024 Junio	283	83	366
2024 Mayo	260	74	334
2024 Abril	224	63	287
2024 Marzo	223	77	300
2024 Febrero	173	61	234
2024 Enero	209	73	282
2023 Diciembre	203	58	261
2023 Noviembre	185	85	270
2023 Octubre	253	98	351
2023 Septiembre	146	74	220
2023 Agosto	106	87	193
2023 Julio	20	47	67

Mostrar todo

Indexada en:

Síguenos:

Estadísticas

Indexada en:

Síguenos:

Estadísticas

Suscríbase a la newsletter